Amag Pharmaceuticals (AMAG) 60.01 $AMAG
AMAG Pharmaceuticals, Inc. to Host Conference Call on May 5, 2015 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2015
GlobeNewswire - Wed Apr 22, 3:30PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2015 before the U.S. financial markets open on Tuesday, May 5, 2015. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will discuss the company's financial results, business update, and growth prospects.
AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals Up 19.9% Since SmarTrend Uptrend Call (AMAG)
Comtex SmarTrend(R) - Wed Apr 22, 11:30AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on February 26th, 2015 at $47.70. In approximately 2 months, AMAG Pharmaceuticals has returned 19.91% as of today's recent price of $57.19.
AMAG: 60.01 (-0.34)
Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.32 (-0.14), BIIB: 401.71 (-28.57), NEO: 4.75 (-0.11), SGMO: 14.70 (-0.84), IMGN: 9.96 (-0.29), AMGN: 167.91 (-1.26), ILMN: 189.59 (-3.01), SVA: 5.10 (unch), BCLI: 4.14 (+0.02), ISRG: 505.92 (-6.85), BABY: 42.15 (-0.01), QURE: 26.09 (-0.28), NURO: 1.28 (-0.03), ABAX: 63.62 (+0.31), GWPH: 121.00 (+0.23), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), AMAG: 60.01 (-0.34), CAT: 84.60 (-0.19), MAA: 76.73 (-0.33), NVS: 104.28 (-1.22)
19.7% Return Seen to Date on SmarTrend AMAG Pharmaceuticals Call (AMAG)
Comtex SmarTrend(R) - Wed Apr 15, 9:53AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on February 26th, 2015 at $47.70. In approximately 2 months, AMAG Pharmaceuticals has returned 19.74% as of today's recent price of $57.11.
AMAG: 60.01 (-0.34)
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
CS: 26.16 (-0.48), CAB: 54.19 (-3.13), BIOS: 5.26 (+0.01), ATTU: 10.79 (+0.41), AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals Has Returned 18.2% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Wed Apr 08, 9:19AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on February 26th, 2015 at $47.70. In approximately 1 month, AMAG Pharmaceuticals has returned 18.19% as of today's recent price of $56.37.
AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals, Inc. to Participate in the 14th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 08, 7:00AM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that Frank Thomas, AMAG's president and chief operating officer, will present at the 14 Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 8:00 a.m. ET in New York. The session will include a company presentation followed by a question and answer session, in which the company's financial results, business update, regulatory status, and growth prospects will be discussed.
AMAG: 60.01 (-0.34)
Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019 - Increase in Associated Disorders with CKD
M2 - Tue Apr 07, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft8dbw/global_chronic) has announced the addition of the "Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019" report to their offering. The Global CKD Drugs market to grow at a CAGR of 1.21% over the period 2014-2019 According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration. Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market. According to the report, the Global CKD Drugs market is predominantly driven by an increase in associated disorders such as hypertension and diabetes, an increase in the aging population, and unmet needs and side effects. The chance of having CKD increases with age and is most common among those aged over 65 years. Further, the report states that the major challenge faced by Global CKD Drugs market is the genericization of major brands. This will create space for generic drug manufacturers. Branded CKD drugs are also exempted from Medicare coverage, resulting in patient incompliance. Key Vendors - Actavis PLC - Amgen Inc. - Johnson & Johnson - F. Hoffmann-La Roche Ltd - Sanofi Other Prominent Vendors - Abbott Laboratories - Akebia Therapeutics - AMAG Pharmaceuticals - Cara Therapeutics - FibroGen - Keryx Biopharmaceuticals - Reata Pharmaceuticals - OPKO Health - Pharmacosmos - Raptor Pharmaceuticals - Regulus Therapeutics - Rockwell Medical - Shield Therapeutics - Takeda Pharmaceuticals - Vifor Pharma Ltd - Xenetic Biosciences - ZS Pharma For more information visit http://www.researchandmarkets.com/research/ft...al_chronic
JNJ: 101.08 (+0.62), ABT: 48.32 (-0.14), ZSPH: 40.97 (-1.90), RPTP: 10.81 (+0.10), OPK: 14.83 (+0.17), AMGN: 167.91 (-1.26), RGLS: 17.49 (-0.80), AMAG: 60.01 (-0.34), AKBA: 8.67 (-0.08), KERX: 11.41 (-0.32)
AMAG Pharmaceuticals Announces New Management Appointments
GlobeNewswire - Wed Apr 01, 3:00PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new management appointments which expand the company's ability to engage with external partners and stakeholders. Linda Lennox has joined the company as vice president of investor relations & corporate communications, assuming responsibilities from Kathryn Carr Payne who has been promoted to vice president of external affairs. In this newly established role for AMAG, Ms. Payne will direct the company's public affairs activities, which includes leading AMAG's public relations, policy and advocacy initiatives at the state and national level.
AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals Shares Up 19.8% Since SmarTrend's Buy Recommendation (AMAG)
Comtex SmarTrend(R) - Fri Mar 27, 11:46AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on February 26th, 2015 at $47.70. In approximately 4 weeks, AMAG Pharmaceuticals has returned 19.82% as of today's recent price of $57.15.
AMAG: 60.01 (-0.34)
Intravenous (IV) Iron Drugs - 2015 Global Strategic Business Report
M2 - Fri Mar 13, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37664v/intravenous_iv) has announced the addition of the "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 17 companies including many key and niche players such as: - Actavis, Inc. (US) - AMAG Pharmaceuticals, Inc. (US) - Fresenius Medical Care AG & Co. KGaA (Germany) - Galenica Ltd. (Switzerland) - Vifor Pharma Ltd. (Switzerland) - Luitpold Pharmaceuticals, Inc. (US) - American Regent, Inc. (US) - Pharmacosmos A/S (Denmark) - Sanofi US (US) - Takeda Pharmaceutical Company Limited (Japan) Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW & TRENDS 3. REGULATORY OVERVIEW 4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS 5. PRODUCT LAUNCHES/APPROVALS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 17 (including Divisions/Subsidiaries 20) - The United States (6) - Japan (2) - Europe (5) - Germany (1) - Rest of Europe (4) - Asia-Pacific (Excluding Japan) (7) For more information visit http://www.researchandmarkets.com/research/37...avenous_iv
ACT: 295.41 (-2.95), AMAG: 60.01 (-0.34)
Akebia Completes Enrolment in Phase II Renal Anemia Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 3:45PM CDT
Akebia Therapeutics (AKBA) completed enrolment in the third and final cohort of a phase II study on AKB-6548, being evaluated for treating patients with anemia related to chronic kidney disease undergoing dialysis.
LCI: 67.40 (unch), AMGN: 167.91 (-1.26), AKBA: 8.67 (-0.08), AMAG: 60.01 (-0.34)
AMAG Pharma prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 6:53PM CST
AMAG: 60.01 (-0.34)
AMAG Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 4:08PM CST
AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals (AMAG) Upgraded From Hold to Buy
at The Street - Fri Feb 20, 9:00AM CST
AMAG Pharmaceuticals (AMAG) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-.
AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals: The Short Thesis Is Wrong
Clinically Sound Investor - at Seeking Alpha - Wed Feb 18, 7:06PM CST
AMAG: 60.01 (-0.34)
Global and USA Transdermal Drug Delivery Market to 2020
M2 - Wed Feb 18, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/87t459/global) has announced the addition of the "Global Transdermal Drug Delivery Market to 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and Swot Investigation" report to their offering. This comprehensive report tackles problems that this vertical growing market faces and evaluates saturated sub-markets. A detailed outlay of its major players is performed including business strategy and future development analysis, merger and acquisition tactics, current product and pipeline entry evaluation and a detailed section on each player's financial situation. This analysis determines the unmet needs of the transdermal drug delivery industry and specific niche areas of market entry. The transdermal drug delivery market has substantial associations within the smoking cessation market, analgesics/pain market, generics market, neuropathic pain market and also the women's health market. In the future it will enter the vaccine and gene therapy markets. Transdermal drug delivery is a complex area that has many driving factors including the unmet need for non-invasive drug delivery systems for pediatric, geriatric and dementia patients. This report describes the current technologies that are propelling the market space and emerging trials and pipeline agents that will make a significant impact on the industry. It examines the current transdermal delivery systems and how generic competition is allowing penetration of new players in the market and saturation of niche areas. Financial figures of the drug delivery market and the transdermal drug delivery space are revealed in this report. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial, business strategy and product review of key players in the transdermal drug delivery industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. In summary, the transdermal drug delivery market has huge opportunities for growth in the areas of dementia (Alzheimer's & Parkinson's Disease), generics, paediatrics and geriatrics. Currently the USA is the most prominent market place, followed by Europe, Asia and Emerging Markets. This report will reveal in-depth analysis of the industry and provide cutting-edge intelligence on the current and future spaces it will penetrate. Key Topics Covered: 1.0 Executive Summary 2.0 Transdermal Drug Delivery 3.0 Biomechanical and Pharmacological Elements Effecting Transdermal Drug Delivery 4.0 Transdermal Drug Delivery Technologies 5.0 How Nanotechnology is Transforming Transdermal Drug Delivery 6.0 Transdermal Drug Delivery and Disease States 7.0 Gene Therapy and Transdermal Drug Delivery 8.0 Vaccines and Transdermal Drug Technology 9.0 Global Drug Delivery Market 10.0 Transdermal Drug Delivery Company Business Profiles and Strategic Evaluation 11.0 Transdermal Drug Delivery Company Financial Analysis 12.0 Current Transdermal Drug Delivery Products on the Market 13.0 In-Depth SWOT Analysis of the Transdermal Drug Delivery Market Companies Mentioned - Actavis - Actelion - GlaxoSmithKline - Bayer - Mylan Pharmaceuticals - Novartis - Upsher-Smith - Ascend Therapeutics - AMAG Pharmaceuticals (Lumara Health, KV Pharm/Ther-Rx Corp) - Janssen Pharmaceuticals - Noven Pharmaceuticals - ProStrakan - Shire - Hercon Pharmaceutical - Kremers Urban Pharmaceuticals - Nitto Denko - Teva Pharmaceutical Industries - Endo International - Teikoku USA - Boehringer Ingelheim - 3M - UCB - ParPharm For more information visit http://www.researchandmarkets.com/research/87t459/global
TEVA: 64.41 (+1.16), AMAG: 60.01 (-0.34), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Lumara Shareholders Are Bailing Out. Shouldn't You?
Alan Biloski - at Seeking Alpha - Tue Feb 17, 3:39PM CST
AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals, Inc. to Host Conference Call on May 5, 2015 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2015
GlobeNewswire - Wed Apr 22, 3:30PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2015 before the U.S. financial markets open on Tuesday, May 5, 2015. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will discuss the company's financial results, business update, and growth prospects.
AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals Up 19.9% Since SmarTrend Uptrend Call (AMAG)
Comtex SmarTrend(R) - Wed Apr 22, 11:30AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on February 26th, 2015 at $47.70. In approximately 2 months, AMAG Pharmaceuticals has returned 19.91% as of today's recent price of $57.19.
AMAG: 60.01 (-0.34)
Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.32 (-0.14), BIIB: 401.71 (-28.57), NEO: 4.75 (-0.11), SGMO: 14.70 (-0.84), IMGN: 9.96 (-0.29), AMGN: 167.91 (-1.26), ILMN: 189.59 (-3.01), SVA: 5.10 (unch), BCLI: 4.14 (+0.02), ISRG: 505.92 (-6.85), BABY: 42.15 (-0.01), QURE: 26.09 (-0.28), NURO: 1.28 (-0.03), ABAX: 63.62 (+0.31), GWPH: 121.00 (+0.23), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), AMAG: 60.01 (-0.34), CAT: 84.60 (-0.19), MAA: 76.73 (-0.33), NVS: 104.28 (-1.22)
19.7% Return Seen to Date on SmarTrend AMAG Pharmaceuticals Call (AMAG)
Comtex SmarTrend(R) - Wed Apr 15, 9:53AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on February 26th, 2015 at $47.70. In approximately 2 months, AMAG Pharmaceuticals has returned 19.74% as of today's recent price of $57.11.
AMAG: 60.01 (-0.34)
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
CS: 26.16 (-0.48), CAB: 54.19 (-3.13), BIOS: 5.26 (+0.01), ATTU: 10.79 (+0.41), AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals Has Returned 18.2% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Wed Apr 08, 9:19AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on February 26th, 2015 at $47.70. In approximately 1 month, AMAG Pharmaceuticals has returned 18.19% as of today's recent price of $56.37.
AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals, Inc. to Participate in the 14th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 08, 7:00AM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that Frank Thomas, AMAG's president and chief operating officer, will present at the 14 Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 8:00 a.m. ET in New York. The session will include a company presentation followed by a question and answer session, in which the company's financial results, business update, regulatory status, and growth prospects will be discussed.
AMAG: 60.01 (-0.34)
Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019 - Increase in Associated Disorders with CKD
M2 - Tue Apr 07, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft8dbw/global_chronic) has announced the addition of the "Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019" report to their offering. The Global CKD Drugs market to grow at a CAGR of 1.21% over the period 2014-2019 According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration. Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market. According to the report, the Global CKD Drugs market is predominantly driven by an increase in associated disorders such as hypertension and diabetes, an increase in the aging population, and unmet needs and side effects. The chance of having CKD increases with age and is most common among those aged over 65 years. Further, the report states that the major challenge faced by Global CKD Drugs market is the genericization of major brands. This will create space for generic drug manufacturers. Branded CKD drugs are also exempted from Medicare coverage, resulting in patient incompliance. Key Vendors - Actavis PLC - Amgen Inc. - Johnson & Johnson - F. Hoffmann-La Roche Ltd - Sanofi Other Prominent Vendors - Abbott Laboratories - Akebia Therapeutics - AMAG Pharmaceuticals - Cara Therapeutics - FibroGen - Keryx Biopharmaceuticals - Reata Pharmaceuticals - OPKO Health - Pharmacosmos - Raptor Pharmaceuticals - Regulus Therapeutics - Rockwell Medical - Shield Therapeutics - Takeda Pharmaceuticals - Vifor Pharma Ltd - Xenetic Biosciences - ZS Pharma For more information visit http://www.researchandmarkets.com/research/ft...al_chronic
JNJ: 101.08 (+0.62), ABT: 48.32 (-0.14), ZSPH: 40.97 (-1.90), RPTP: 10.81 (+0.10), OPK: 14.83 (+0.17), AMGN: 167.91 (-1.26), RGLS: 17.49 (-0.80), AMAG: 60.01 (-0.34), AKBA: 8.67 (-0.08), KERX: 11.41 (-0.32)
AMAG Pharmaceuticals Announces New Management Appointments
GlobeNewswire - Wed Apr 01, 3:00PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new management appointments which expand the company's ability to engage with external partners and stakeholders. Linda Lennox has joined the company as vice president of investor relations & corporate communications, assuming responsibilities from Kathryn Carr Payne who has been promoted to vice president of external affairs. In this newly established role for AMAG, Ms. Payne will direct the company's public affairs activities, which includes leading AMAG's public relations, policy and advocacy initiatives at the state and national level.
AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals Shares Up 19.8% Since SmarTrend's Buy Recommendation (AMAG)
Comtex SmarTrend(R) - Fri Mar 27, 11:46AM CDT
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on February 26th, 2015 at $47.70. In approximately 4 weeks, AMAG Pharmaceuticals has returned 19.82% as of today's recent price of $57.15.
AMAG: 60.01 (-0.34)
Intravenous (IV) Iron Drugs - 2015 Global Strategic Business Report
M2 - Fri Mar 13, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37664v/intravenous_iv) has announced the addition of the "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 17 companies including many key and niche players such as: - Actavis, Inc. (US) - AMAG Pharmaceuticals, Inc. (US) - Fresenius Medical Care AG & Co. KGaA (Germany) - Galenica Ltd. (Switzerland) - Vifor Pharma Ltd. (Switzerland) - Luitpold Pharmaceuticals, Inc. (US) - American Regent, Inc. (US) - Pharmacosmos A/S (Denmark) - Sanofi US (US) - Takeda Pharmaceutical Company Limited (Japan) Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW & TRENDS 3. REGULATORY OVERVIEW 4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS 5. PRODUCT LAUNCHES/APPROVALS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 17 (including Divisions/Subsidiaries 20) - The United States (6) - Japan (2) - Europe (5) - Germany (1) - Rest of Europe (4) - Asia-Pacific (Excluding Japan) (7) For more information visit http://www.researchandmarkets.com/research/37...avenous_iv
ACT: 295.41 (-2.95), AMAG: 60.01 (-0.34)
Akebia Completes Enrolment in Phase II Renal Anemia Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 3:45PM CDT
Akebia Therapeutics (AKBA) completed enrolment in the third and final cohort of a phase II study on AKB-6548, being evaluated for treating patients with anemia related to chronic kidney disease undergoing dialysis.
LCI: 67.40 (unch), AMGN: 167.91 (-1.26), AKBA: 8.67 (-0.08), AMAG: 60.01 (-0.34)
AMAG Pharma prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 6:53PM CST
AMAG: 60.01 (-0.34)
AMAG Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 4:08PM CST
AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals (AMAG) Upgraded From Hold to Buy
at The Street - Fri Feb 20, 9:00AM CST
AMAG Pharmaceuticals (AMAG) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B-.
AMAG: 60.01 (-0.34)
AMAG Pharmaceuticals: The Short Thesis Is Wrong
Clinically Sound Investor - at Seeking Alpha - Wed Feb 18, 7:06PM CST
AMAG: 60.01 (-0.34)
Global and USA Transdermal Drug Delivery Market to 2020
M2 - Wed Feb 18, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/87t459/global) has announced the addition of the "Global Transdermal Drug Delivery Market to 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and Swot Investigation" report to their offering. This comprehensive report tackles problems that this vertical growing market faces and evaluates saturated sub-markets. A detailed outlay of its major players is performed including business strategy and future development analysis, merger and acquisition tactics, current product and pipeline entry evaluation and a detailed section on each player's financial situation. This analysis determines the unmet needs of the transdermal drug delivery industry and specific niche areas of market entry. The transdermal drug delivery market has substantial associations within the smoking cessation market, analgesics/pain market, generics market, neuropathic pain market and also the women's health market. In the future it will enter the vaccine and gene therapy markets. Transdermal drug delivery is a complex area that has many driving factors including the unmet need for non-invasive drug delivery systems for pediatric, geriatric and dementia patients. This report describes the current technologies that are propelling the market space and emerging trials and pipeline agents that will make a significant impact on the industry. It examines the current transdermal delivery systems and how generic competition is allowing penetration of new players in the market and saturation of niche areas. Financial figures of the drug delivery market and the transdermal drug delivery space are revealed in this report. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial, business strategy and product review of key players in the transdermal drug delivery industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. In summary, the transdermal drug delivery market has huge opportunities for growth in the areas of dementia (Alzheimer's & Parkinson's Disease), generics, paediatrics and geriatrics. Currently the USA is the most prominent market place, followed by Europe, Asia and Emerging Markets. This report will reveal in-depth analysis of the industry and provide cutting-edge intelligence on the current and future spaces it will penetrate. Key Topics Covered: 1.0 Executive Summary 2.0 Transdermal Drug Delivery 3.0 Biomechanical and Pharmacological Elements Effecting Transdermal Drug Delivery 4.0 Transdermal Drug Delivery Technologies 5.0 How Nanotechnology is Transforming Transdermal Drug Delivery 6.0 Transdermal Drug Delivery and Disease States 7.0 Gene Therapy and Transdermal Drug Delivery 8.0 Vaccines and Transdermal Drug Technology 9.0 Global Drug Delivery Market 10.0 Transdermal Drug Delivery Company Business Profiles and Strategic Evaluation 11.0 Transdermal Drug Delivery Company Financial Analysis 12.0 Current Transdermal Drug Delivery Products on the Market 13.0 In-Depth SWOT Analysis of the Transdermal Drug Delivery Market Companies Mentioned - Actavis - Actelion - GlaxoSmithKline - Bayer - Mylan Pharmaceuticals - Novartis - Upsher-Smith - Ascend Therapeutics - AMAG Pharmaceuticals (Lumara Health, KV Pharm/Ther-Rx Corp) - Janssen Pharmaceuticals - Noven Pharmaceuticals - ProStrakan - Shire - Hercon Pharmaceutical - Kremers Urban Pharmaceuticals - Nitto Denko - Teva Pharmaceutical Industries - Endo International - Teikoku USA - Boehringer Ingelheim - 3M - UCB - ParPharm For more information visit http://www.researchandmarkets.com/research/87t459/global
TEVA: 64.41 (+1.16), AMAG: 60.01 (-0.34), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)
Lumara Shareholders Are Bailing Out. Shouldn't You?
Alan Biloski - at Seeking Alpha - Tue Feb 17, 3:39PM CST
AMAG: 60.01 (-0.34)
